AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26215644 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, individually tailored occupational rehabilitation intervention using acceptance and commitment therapy dialogue and individual-placement-and-support-inspired tools.
Number of subjects: 0
Study 26215644 — intervention group
Group type: COMPARATOR
Intervention: Control group with identical inclusion and exclusion criteria except for municipality of residence.
Number of subjects: 0
Study 26215644 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome analysis of co-morbidity and socio-economic status as effect modifiers of the intervention effect on return to work.
Number of subjects: 0
Study 24124710 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP monitoring (Group A, B, C)
Number of subjects: 216
Study 24124710 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (ICP monitoring)
Number of subjects: 216
Study 24124710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol dosage in Groups A, B, C
Number of subjects: 216
Study 24124710 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ICP monitoring)
Number of subjects: 216
Study 20889295 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 40
Study 20889295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18339160 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) using propofol and remifentanil
Number of subjects: 18
Study 18339160 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 18
Study 16768051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol 2 mg/day
Number of subjects: 45
Study 16768051 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol 50 microg/day
Number of subjects: 45
Study 15641867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 to 80 mg b.i.d.
Number of subjects: 296
Study 15641867 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 3 to 5 mg b.i.d.
Number of subjects: 296
Study 11384791 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines administered by paramedics
Number of subjects: 205
Study 11384791 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 205
Study 11384791 — intervention group
Group type: COMPARATOR
Intervention: Control of status epilepticus prior to arrival at the emergency department
Number of subjects: 205
Study 9454352 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 3 Gy irradiation
Number of subjects: 585
Study 9454352 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 5 Gy irradiation
Number of subjects: 585
Study 9454352 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 7 Gy irradiation
Number of subjects: 585
Study 9454352 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin for 7 days
Number of subjects: 585
Study 9454352 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin for 14 days
Number of subjects: 585
Study 9454352 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicyl acid (ASS) for 14 days
Number of subjects: 585
Study 9454352 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no prophylactic therapy)
Number of subjects: 585
Study 8508283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine with NSAID continued
Number of subjects: 149
Study 8508283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine with NSAID discontinued
Number of subjects: 149
Study 8508283 — intervention group
Group type: COMPARATOR
Intervention: Placebo with NSAID discontinued
Number of subjects: 149
Study 3789787 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher copper content formulas
Number of subjects: 145
Study 3789787 — intervention group
Group type: COMPARATOR
Intervention: Lower copper content formulas
Number of subjects: 145
Study 29769507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (1μg/kg) with intravenous fentanyl (1μg/kg)
Number of subjects: 120
Study 29769507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (1μg/kg) with intravenous fentanyl (1μg/kg)
Number of subjects: 120
Study 29769507 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (2μg/kg)
Number of subjects: 120
Study 26865356 — intervention group
Group type: EXPERIMENTAL
Intervention: Short retention interval (RI) with reporting-error-sensitive measures (correspondence rate and inflation ratio)
Number of subjects: 480
Study 26865356 — intervention group
Group type: COMPARATOR
Intervention: Long retention interval (RI) with reporting-error-sensitive measures (correspondence rate and inflation ratio)
Number of subjects: 480
Study 26865356 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast location in classroom
Number of subjects: 480
Study 26865356 — intervention group
Group type: COMPARATOR
Intervention: Breakfast location in cafeteria
Number of subjects: 480
Study 26865356 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch reports
Number of subjects: 480
Study 26865356 — intervention group
Group type: COMPARATOR
Intervention: Breakfast reports
Number of subjects: 480
Study 25058311 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rosmarinic acid spearmint tea
Number of subjects: 62
Study 25058311 — intervention group
Group type: COMPARATOR
Intervention: Commercially available spearmint tea
Number of subjects: 62
Study 22037055 — intervention group
Group type: EXPERIMENTAL
Intervention: High genetic risk scenario
Number of subjects: 49
Study 22037055 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic risk scenario
Number of subjects: 49
Study 22037055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low genetic risk scenario
Number of subjects: 49
Study 22037055 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 49
Study 22037055 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 49
Study 20797502 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study 20797502 — intervention group
Group type: COMPARATOR
Intervention: Coronary stents
Number of subjects: 0
Study 17940147 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded training program (13 weeks)
Number of subjects: 532
Study 17940147 — intervention group
Group type: COMPARATOR
Intervention: Standard training program (8 weeks)
Number of subjects: 532
Study 16847231 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with simple sutured crura (nonmesh group, n = 20)
Number of subjects: 40
Study 16847231 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication with prosthetic hiatal closure (mesh group, n = 20)
Number of subjects: 40
Study 16847231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (nonmesh and mesh)
Number of subjects: 40
Study 12788263 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills for Adolescence (SFA) program
Number of subjects: 7426
Study 12788263 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 7426
Study 10709884 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with 13 g l(‐1) of protein
Number of subjects: 0
Study 10709884 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with 15 g l(‐1) of protein
Number of subjects: 0
Study 10709884 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with 18/20 g l(‐1) of protein
Number of subjects: 0
Study 10709884 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish weaning foods
Number of subjects: 0
Study 10709884 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian weaning foods
Number of subjects: 0
Study 10709884 — intervention group
Group type: EXPERIMENTAL
Intervention: All formula groups
Number of subjects: 0
Study 10709884 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 8684510 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine capsules (up to 10 mg per day)
Number of subjects: 35
Study 8684510 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine patch (transdermal application)
Number of subjects: 35
Study 8684510 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (in open follow-up study)
Number of subjects: 35
Study 1627368 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1)
Number of subjects: 59
Study 1627368 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/m2 weekly for 12 courses (arm 2)
Number of subjects: 59
Study 6378118 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dialysis
Number of subjects: 24
Study 6378118 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 24
Study 31248744 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning plus education intervention (n=52)
Number of subjects: 102
Study 31248744 — intervention group
Group type: COMPARATOR
Intervention: Education-only intervention (n=50)
Number of subjects: 102
Study 29960876 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART boost arm
Number of subjects: 60
Study 29960876 — intervention group
Group type: COMPARATOR
Intervention: SIB-IMRT (control arm)
Number of subjects: 60
Study 26463644 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist palliative care (SPC)
Number of subjects: 513
Study 26463644 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 513
Study 25010107 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of self-efficacy
Number of subjects: 141
Study 22895810 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (500 mg/day)
Number of subjects: 133
Study 22895810 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (500 mg/day)
Number of subjects: 133
Study 22895810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-L-carnitine (500 mg/day magnesium and 500 mg/day L-carnitine)
Number of subjects: 133
Study 22895810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study 19800827 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated based on desired final optimum thyroid mass value (m(f)=0.24 m(0)/U(0)) in GR2
Number of subjects: 97
Study 19800827 — intervention group
Group type: COMPARATOR
Intervention: Calculated based on fixed absorbed dose of 400 Gy in GR3
Number of subjects: 97
Study 19800827 — intervention group
Group type: COMPARATOR
Intervention: Calculated based on fixed absorbed dose of 100 Gy in GR1
Number of subjects: 97
Study 19800827 — intervention group
Group type: EXPERIMENTAL
Intervention: Average activity administered to GR2
Number of subjects: 97
Study 19800827 — intervention group
Group type: COMPARATOR
Intervention: Average activity administered to GR3
Number of subjects: 97
Study 19800827 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid absorbed dose in GR2
Number of subjects: 97
Study 19800827 — intervention group
Group type: COMPARATOR
Intervention: Thyroid absorbed dose in GR3
Number of subjects: 97
Study 18077922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica
Number of subjects: 88
Study 18077922 — intervention group
Group type: COMPARATOR
Intervention: Base cream (vehicle)
Number of subjects: 88
Study 18077922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica (in cold and dry conditions)
Number of subjects: 88
Study 15665010 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU recFSH plus 75 IU recLH (lutropin alpha)
Number of subjects: 127
Study 15665010 — intervention group
Group type: COMPARATOR
Intervention: 150 IU recFSH (follitropin alpha)
Number of subjects: 127
Study 12399266 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine supplementation (6 g/d)
Number of subjects: 42
Study 12399266 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 42
Study 9933276 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of MCA territory hypodensity on hyperacute CT scans
Number of subjects: 50
Study 7755536 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session telephone behavior therapy program
Number of subjects: 42
Study 7755536 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 42
Study 7755536 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone behavior therapy
Number of subjects: 42
Study 2406658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan
Number of subjects: 0
Study 2406658 — intervention group
Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 0
Study 6270809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (2.5 mg i.v.)
Number of subjects: 11
Study 6270809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30990131 — intervention group
Group type: EXPERIMENTAL
Intervention: Process oriented goal setting
Number of subjects: 41
Study 30990131 — intervention group
Group type: COMPARATOR
Intervention: Outcome oriented goal setting
Number of subjects: 41
Study 30990131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during retention trials
Number of subjects: 41
Study 30990131 — intervention group
Group type: EXPERIMENTAL
Intervention: Process group on the 10th retention trial
Number of subjects: 41
Study 28315010 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine with benzodiazepine
Number of subjects: 40
Study 28315010 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl with benzodiazepine
Number of subjects: 40
Study 26413928 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote group (RG)
Number of subjects: 300
Study 26413928 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 300
Study 24157401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 0
Study 24157401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (AVP)
Number of subjects: 0
Study 24157401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) and vasopressin (AVP)
Number of subjects: 0
Study 24157401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22513499 — intervention group
Group type: EXPERIMENTAL
Intervention: Early occlusal loading at 1 week after surgery
Number of subjects: 12
Study 22513499 — intervention group
Group type: COMPARATOR
Intervention: Early occlusal loading at 6 weeks after surgery
Number of subjects: 12
Study 19459090 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis (self-help)
Number of subjects: 58
Study 19459090 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 58
Study 17117373 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 523
Study 17117373 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted regression model
Number of subjects: 523
Study 16011816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg, 10 mg, or 20 mg
Number of subjects: 0
Study 16011816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12088804 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (n = 30)
Number of subjects: 60
Study 12088804 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (n = 30)
Number of subjects: 60
Study 12088804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthetics
Number of subjects: 60
Study 9860409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral norfloxacin 400 mg/12 h for 7 days
Number of subjects: 56
Study 9860409 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin plus intravenous ceftriaxone 2 g daily during the first 3 days of admission
Number of subjects: 56
Study 9860409 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin plus intravenous ceftriaxone
Number of subjects: 56
Study 8593198 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride dentifrice (SnF2)
Number of subjects: 0
Study 8593198 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (placebo)
Number of subjects: 0
Study 2762182 — intervention group
Group type: EXPERIMENTAL
Intervention: APF foam (0.9 g)
Number of subjects: 20
Study 2762182 — intervention group
Group type: COMPARATOR
Intervention: APF gel (4 g)
Number of subjects: 20
Study 1155873 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous agar oral administration, 125 mg before each of the seven formula feedings
Number of subjects: 0
Study 1155873 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous agar administration, 250 mg before three of the seven formula feedings
Number of subjects: 0
Study 1155873 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous phototherapy for 96 hours
Number of subjects: 0
Study 1155873 — intervention group
Group type: COMPARATOR
Intervention: Control group with no prophylaxis
Number of subjects: 0
Study 31736406 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training group (CTG)
Number of subjects: 23
Study 31736406 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study 30195198 — intervention group
Group type: EXPERIMENTAL
Intervention: Edentulous participants (0 teeth)
Number of subjects: 20548
Study 30195198 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with 1-9 teeth
Number of subjects: 20548
Study 30195198 — intervention group
Group type: COMPARATOR
Intervention: Participants with 20 or more teeth
Number of subjects: 20548
Study 28458115 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone treatment (n=6)
Number of subjects: 11
Study 28458115 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n=5)
Number of subjects: 11
Study 28458115 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=4)
Number of subjects: 11
Study 25504992 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet
Number of subjects: 80
Study 25504992 — intervention group
Group type: COMPARATOR
Intervention: Mask
Number of subjects: 80
Study 24159904 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL) curriculum for brief intervention skills
Number of subjects: 56
Study 24159904 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 56
Study 20948432 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine LAI 300 mg/2 weeks
Number of subjects: 1065
Study 20948432 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine LAI 150 mg/2 weeks
Number of subjects: 1065
Study 20948432 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine LAI 405 mg/4 weeks
Number of subjects: 1065
Study 18441720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oxalate food consumption
Number of subjects: 484
Study 18441720 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated oxalate intake
Number of subjects: 484
Study 18441720 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of various food items high in oxalate content
Number of subjects: 484
Study 17315804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-health workshop
Number of subjects: 830
Study 14531866 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient containing skin-related lipids (Locobase Repair)
Number of subjects: 30
Study 14531866 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum-based emollient
Number of subjects: 30
Study 11822223 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 6 days
Number of subjects: 192
Study 11822223 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin 1 g once daily (single dose)
Number of subjects: 192
Study 11822223 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg b.i.d. for 14 days
Number of subjects: 192
Study 11822223 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg b.i.d. for 7 days
Number of subjects: 192
Study 9762946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (2 g amino acid/M2/dose twice daily)
Number of subjects: 24
Study 9762946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine)
Number of subjects: 24
Study 7924856 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.1% eyedrops
Number of subjects: 64
Study 7924856 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 0.03% eyedrops
Number of subjects: 64
Study 3150273 — intervention group
Group type: EXPERIMENTAL
Intervention: FLM 5011
Number of subjects: 0
Study 3150273 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppressive therapy
Number of subjects: 0
Study 31507095 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counseling sessions and tailored text messages
Number of subjects: 150
Study 31507095 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle (Control)
Number of subjects: 150
Study 30376410 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated group
Number of subjects: 60
Study 28419204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin‐IPV high dose
Number of subjects: 500
Study 28419204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin‐IPV medium dose
Number of subjects: 500
Study 28419204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin‐IPV low dose
Number of subjects: 500
Study 28419204 — intervention group
Group type: COMPARATOR
Intervention: Trivalent oral polio vaccine
Number of subjects: 500
Study 28419204 — intervention group
Group type: COMPARATOR
Intervention: Salk strain‐based IPV
Number of subjects: 500
Study 25923490 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (low-dose)
Number of subjects: 89
Study 25923490 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pre-surgery QTc-duration
Number of subjects: 89
Study 25923490 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged pre-surgery QTc-duration
Number of subjects: 89
Study 25923490 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-QTc (n=8)
Number of subjects: 89
Study 22236169 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CH) intracanal medication for 14 days
Number of subjects: 60
Study 22236169 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study 22133165 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological multicomponent group therapy (MAKS) - motor stimulation, practice in activities of daily living, cognitive stimulation, conducted in groups of ten patients for 2 hours, 6 days a week for 12 months.
Number of subjects: 98